TrialBlood advances2025

Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study.

Nirav N Shah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.